NCT05872854 2026-02-09
RW-HPN-MF-01
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
Clinical Trials
4 trialsNCT06149247 2025-08-20
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Soligenix
Phase 2 Completed
NCT05380635 2023-06-07
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
Soligenix
Phase 2 Completed
NCT02448381 2022-04-15
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Soligenix
Phase 3 Completed